Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal types of cancer in the
United States. Surgical resection remains the only curative treatment, but fewer than 20% of …

Pancreatic ductal adenocarcinoma (PDAC) is an incurable lethal disease whose incidence
rate is growing. There is no effective screening for detection of early stage tumors and, in …

Background: Pancreatic ductal adenocarcinoma (PDAC) is characterised by an extremely
poor overall survival (OS) compared to other solid tumours. As the incidence of the disease …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-
year survival rate of approximately 5%. Several target agents have been tested in PDAC, but …

The prognosis of advanced pancreatic adenocarcinoma is still poor nowadays. Gemcitabine
in monotherapy (30-min infusion) has been the standard of treatment during the last decade …

Patients with pancreatic cancer normally present with advanced disease that is lethal and
notoriously difficult to treat. However, clinical developments over the past decade have been …

Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second cause of
cancer-related death in 2030. PDAC is the poorest prognostic tumor of the digestive tract …

Background In contrast to other cancers, survival rates for pancreatic ductal
adenocarcinoma (PDAC) patients have improved but minimally over the past thirty years …

Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020.
The survival rates for patients with other gastrointestinal malignancies have increased …

Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC)
have lagged behind advances made in the treatment of many other malignancies over the …